Clinical Trial Update: Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin [Phase 3]

View source ↗

Summary

Phase 3 trial comparing rivaroxaban to enoxaparin for venous thromboembolism prophylaxis after gynecologic pelvic cancer surgery.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Gynecologic Cancer
• Venous Thromboembolism

Drugs mentioned

• Enoxaparin (enoxaparin sodium)
• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: André Luiz Malavasi Longo de Oliveira | Conditions: Cancer, Rivaroxaban | Phase 3 | Status: UNKNOWN